Glaukos (NYSE:GKOS) Price Target Raised to $116.00 at BTIG Research

Glaukos (NYSE:GKOS) had its price target boosted by BTIG Research from $104.00 to $116.00 in a research note released on Thursday morning, MarketBeat Ratings reports. BTIG Research currently has a buy rating on the medical instruments supplier’s stock.

Several other research analysts have also commented on the stock. Truist Financial decreased their price target on shares of Glaukos from $126.00 to $120.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Wells Fargo & Company lifted their price target on shares of Glaukos from $86.00 to $92.00 and gave the company an “equal weight” rating in a report on Thursday, July 31st. Needham & Company LLC lifted their price target on shares of Glaukos from $115.00 to $117.00 and gave the company a “buy” rating in a report on Thursday. Mizuho set a $130.00 price objective on shares of Glaukos in a research report on Thursday, July 31st. Finally, William Blair upgraded shares of Glaukos to a “strong-buy” rating in a research report on Thursday, July 31st. One research analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $118.62.

Glaukos Trading Up 14.4%

NYSE GKOS opened at $88.21 on Thursday. Glaukos has a one year low of $73.16 and a one year high of $163.71. The company has a 50-day simple moving average of $85.55 and a 200-day simple moving average of $91.57. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.69 and a current ratio of 5.51. The firm has a market capitalization of $5.06 billion, a PE ratio of -57.28 and a beta of 0.76.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, October 29th. The medical instruments supplier reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.11. Glaukos had a negative net margin of 18.65% and a negative return on equity of 7.53%. The business had revenue of $133.54 million during the quarter, compared to analyst estimates of $122.55 million. During the same period in the previous year, the business posted ($0.28) EPS. The company’s quarterly revenue was up 38.1% on a year-over-year basis. Glaukos has set its FY 2025 guidance at EPS. On average, equities analysts forecast that Glaukos will post -1.08 earnings per share for the current year.

Institutional Trading of Glaukos

A number of hedge funds and other institutional investors have recently made changes to their positions in GKOS. Bessemer Group Inc. raised its position in shares of Glaukos by 133.9% during the 1st quarter. Bessemer Group Inc. now owns 276 shares of the medical instruments supplier’s stock worth $27,000 after buying an additional 158 shares in the last quarter. First Horizon Advisors Inc. raised its position in shares of Glaukos by 72.9% during the 1st quarter. First Horizon Advisors Inc. now owns 377 shares of the medical instruments supplier’s stock worth $37,000 after buying an additional 159 shares in the last quarter. Park Place Capital Corp raised its position in shares of Glaukos by 68.4% during the 2nd quarter. Park Place Capital Corp now owns 399 shares of the medical instruments supplier’s stock worth $41,000 after buying an additional 162 shares in the last quarter. AlphaQuest LLC raised its position in shares of Glaukos by 5,754.5% during the 2nd quarter. AlphaQuest LLC now owns 644 shares of the medical instruments supplier’s stock worth $67,000 after buying an additional 633 shares in the last quarter. Finally, Smartleaf Asset Management LLC raised its position in shares of Glaukos by 16.2% during the 2nd quarter. Smartleaf Asset Management LLC now owns 973 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 136 shares in the last quarter. 99.04% of the stock is currently owned by institutional investors.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.